Clinical trials
Completed Neoplasms trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
206 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 5 |
| 2008 | 7 |
| 2009 | 4 |
| 2010 | 10 |
| 2011 | 4 |
| 2012 | 10 |
| 2013 | 14 |
| 2014 | 9 |
| 2015 | 10 |
| 2016 | 17 |
| 2017 | 5 |
| 2018 | 10 |
| 2019 | 10 |
| 2020 | 7 |
| 2021 | 21 |
| 2022 | 20 |
| 2023 | 16 |
| 2024 | 11 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 206 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd. | 11 |
| National Cancer Institute (NCI) | 10 |
| Bayer | 7 |
| Capital Medical University | 6 |
| The University of Hong Kong | 6 |
| Hoffmann-La Roche | 5 |
| Peking University First Hospital | 5 |
| Pfizer | 5 |
| The First Affiliated Hospital of Xiamen University | 5 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 206 |
| Carcinoma, Non-Small-Cell Lung | 15 |
| Breast Neoplasms | 9 |
| Colorectal Neoplasms | 9 |
| Digestive System Neoplasms | 9 |
| Neoplasms by Site | 9 |
| Digestive System Diseases | 8 |
| Lung Neoplasms | 8 |
| Esophageal Neoplasms | 7 |
| Stomach Neoplasms | 7 |
Trials
Showing 1 to 25 of 206. Each trial links to its page on Pharma Observatory.
106 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.